Literature DB >> 25956815

Non-dopamine receptor ligands for the treatment of Parkinson's disease. Insight into the related chemical/property space.

Yan A Ivanenkov1,2,3, Mark S Veselov4,5,6, Nina V Chufarova4,6, Alexander G Majouga5,6, Anna A Kudryavceva4, Alexandre V Ivachtchenko7.   

Abstract

Extensive biochemical and clinical studies have increasingly recognized Parkinson's disease as a highly complex and multi-faceted neurological disorder having branched non-motor symptoms including sleep disorders, pain, constipation, psychosis, depression, and fatigue. A wide range of biological targets in the brain deeply implicated in this pathology resulted in a plethora of novel small-molecule compounds with promising activity. This review thoroughly describes the chemical space of non-dopamine receptor ligands in terms of diversity, isosteric/bioisosteric morphing, and molecular descriptors.

Entities:  

Keywords:  Bioisosteres; Descriptors; Diversity; Drugs; Non-dopamine; Parkinson’s disease

Mesh:

Substances:

Year:  2015        PMID: 25956815     DOI: 10.1007/s11030-015-9598-y

Source DB:  PubMed          Journal:  Mol Divers        ISSN: 1381-1991            Impact factor:   2.943


  57 in total

Review 1.  Effects of cholinesterase inhibitors in Parkinson's disease dementia: a review of clinical data.

Authors:  Teus van Laar; Peter Paul De Deyn; Dag Aarsland; Paolo Barone; James E Galvin
Journal:  CNS Neurosci Ther       Date:  2010-07-07       Impact factor: 5.243

2.  Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase.

Authors:  László E Kiss; Humberto S Ferreira; Leonel Torrão; Maria João Bonifácio; P Nuno Palma; Patrício Soares-da-Silva; David A Learmonth
Journal:  J Med Chem       Date:  2010-04-22       Impact factor: 7.446

Review 3.  Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias.

Authors:  Olivier Rascol; Susan Fox; Fabrizio Gasparini; Christopher Kenney; Thérèse Di Paolo; Baltazar Gomez-Mancilla
Journal:  Parkinsonism Relat Disord       Date:  2014-05-14       Impact factor: 4.891

4.  Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease.

Authors:  Kathryn A Chung; Brenna M Lobb; John G Nutt; Fay B Horak
Journal:  Neurology       Date:  2010-09-01       Impact factor: 9.910

5.  Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study).

Authors:  Peter A Lewitt; Robert A Hauser; Mei Lu; Anthony P Nicholas; William Weiner; Nicholas Coppard; Mika Leinonen; Juha-Matti Savola
Journal:  Neurology       Date:  2012-06-27       Impact factor: 9.910

Review 6.  Autophagy in aging and neurodegenerative diseases: implications for pathogenesis and therapy.

Authors:  Chen-Chen Tan; Jin-Tai Yu; Meng-Shan Tan; Teng Jiang; Xi-Chen Zhu; Lan Tan
Journal:  Neurobiol Aging       Date:  2013-11-28       Impact factor: 4.673

Review 7.  Rivastigmine in Parkinson's disease dementia.

Authors:  Shilpa Chitnis; Jayaraman Rao
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-08       Impact factor: 4.481

Review 8.  Multiple roles for nicotine in Parkinson's disease.

Authors:  Maryka Quik; Luping Z Huang; Neeraja Parameswaran; Tanuja Bordia; Carla Campos; Xiomara A Perez
Journal:  Biochem Pharmacol       Date:  2009-05-09       Impact factor: 5.858

9.  Discovery of novel indolinone-based, potent, selective and brain penetrant inhibitors of LRRK2.

Authors:  Thomas Troxler; Paulette Greenidge; Kaspar Zimmermann; Sandrine Desrayaud; Peter Drückes; Tatjana Schweizer; Daniela Stauffer; Giorgio Rovelli; Derya R Shimshek
Journal:  Bioorg Med Chem Lett       Date:  2013-05-24       Impact factor: 2.823

Review 10.  Neural substrates linking balance control and anxiety.

Authors:  Carey D Balaban
Journal:  Physiol Behav       Date:  2002-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.